Versetti Family Office advances discussion on longevity innovation at Global Summit

The 6th Annual Timepie Longevity Summit, a premier global gathering of longevity experts, researchers, and investors, recently concluded with a focus on the intersection of science, technology, and entrepreneurship in advancing human lifespan and healthspan. Angel Versetti, Founder and CEO of the Versetti Family Office, emerged as a key voice at the event, addressing critical challenges and opportunities in the longevity industry. In his keynote speech, Versetti highlighted the structural and operational barriers hindering the scaling of early-stage longevity startups and underscored the necessity of fostering synergy between scientific innovation and commercial application. He introduced the Versetti Family Office’s venture-builder model, which aims to address these challenges by unlocking capital and supporting startups dedicated to lifespan-extending discoveries. Versetti also emphasized China’s growing role in the longevity ecosystem, citing its world-class life sciences IP and contract research organizations (CROs) as key drivers of global progress. He expressed enthusiasm for potential collaborations with Chinese universities and labs. During a media interaction, Versetti shared insights on promising longevity interventions while cautioning against unverified or marketing-driven treatments. He drew parallels between modern longevity pioneers like Bryan Johnson and historical figures such as Alexander Bogdanov, who tragically died from self-experimentation. Versetti also stressed the importance of global collaboration in longevity science, warning that geopolitical polarization could impede collective progress. He praised the Timepie Longevity Forum for fostering inclusive dialogue among experts from the United States, United Kingdom, Europe, Russia, Singapore, and China. The Versetti Family Office’s participation at the summit reaffirms its commitment to advancing longevity science through responsible innovation, strategic investments, and active engagement in global research discussions.